Theralase Technologies (FRA:TTX) Cyclically Adjusted Book per Share: €0.02 (As of Mar. 2026)


FRA:TTX Theralase Technologies Inc FRA:TTX
47 GF Score
Price €0.16
GF Value €0.10
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Theralase Technologies Cyclically Adjusted Book per Share?

Theralase Technologies FRA:TTX +3.97% 47 Cyclically Adjusted Book per Share is €0.02 as of Mar. 2026. GuruFocus rates FRA:TTX with a GF Score™ of 47/100 and a GF Value™ of €0.10 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Theralase Technologies's adjusted book value per share for the three months ended in Mar. 2026 was €0.005. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.02 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Theralase Technologies's average Cyclically Adjusted Book Growth Rate was -25.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -9.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -4.00% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -5.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-08), Theralase Technologies's current stock price is €0.157. Theralase Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €0.02. Theralase Technologies's Cyclically Adjusted PB Ratio of today is 7.85.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Theralase Technologies was 13.75. The lowest was 3.13. And the median was 6.50.


Theralase Technologies  (FRA:TTX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Theralase Technologies's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.157/0.02
=7.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Theralase Technologies was 13.75. The lowest was 3.13. And the median was 6.50.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Theralase Technologies Cyclically Adjusted Book per Share Related Terms


Theralase Technologies Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Theralase Technologies's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theralase Technologies Cyclically Adjusted Book per Share Chart

Theralase Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.03 0.02 0.02 0.02

Theralase Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 0.02 0.02 0.02

FRA:TTX vs ABT, SYK, MDT: Cyclically Adjusted Book per Share Comparison

For the Medical Devices subindustry, Theralase Technologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralase Technologies Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's Cyclically Adjusted PB Ratio falls into.


FRA:TTX
47GF Score
Theralase Technologies Inc FRA:TTX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theralase Technologies Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Theralase Technologies's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.005/132.2623*132.2623
=0.005

Current CPI (Mar. 2026) = 132.2623.

Theralase Technologies Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.028 102.002 0.036
201609 0.018 101.765 0.023
201612 0.033 101.449 0.043
201703 0.025 102.634 0.032
201706 0.020 103.029 0.026
201709 0.017 103.345 0.022
201712 0.011 103.345 0.014
201803 0.005 105.004 0.006
201806 0.006 105.557 0.008
201809 0.003 105.636 0.004
201812 0.005 105.399 0.006
201903 0.014 106.979 0.017
201906 0.012 107.690 0.015
201909 0.056 107.611 0.069
201912 0.046 107.769 0.056
202003 0.040 107.927 0.049
202006 0.036 108.401 0.044
202009 0.031 108.164 0.038
202012 0.029 108.559 0.035
202103 0.027 110.298 0.032
202106 0.024 111.720 0.028
202109 0.021 112.905 0.025
202112 0.017 113.774 0.020
202203 0.012 117.646 0.013
202206 0.009 120.806 0.010
202209 0.013 120.648 0.014
202212 0.010 120.964 0.011
202303 0.006 122.702 0.006
202306 0.006 124.203 0.006
202309 0.005 125.230 0.005
202312 0.006 125.072 0.006
202403 0.006 126.258 0.006
202406 0.005 127.522 0.005
202409 0.006 127.285 0.006
202412 0.006 127.364 0.006
202503 0.003 129.181 0.003
202506 0.003 129.892 0.003
202509 0.003 130.287 0.003
202512 0.004 130.366 0.004
202603 0.005 132.262 0.005

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €0.02 mean?
Theralase Technologies (FRA:TTX) has a Cyclically Adjusted Book per Share of €0.02 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Theralase Technologies and its competitors.
Is Theralase Technologies' Cyclically Adjusted Book per Share too high?
Theralase Technologies' current Cyclically Adjusted Book per Share is €0.02. Overall, Theralase Technologies has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' Cyclically Adjusted Book per Share compare to ABT and SYK?
Theralase Technologies' Cyclically Adjusted Book per Share of €0.02 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Book per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Theralase Technologies and its competitors. Theralase Technologies's current Cyclically Adjusted Book per Share is €0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (FRA:TTX) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.10, compared to a current price of €0.16 — trading 57% above its estimated fair value. The current Cyclically Adjusted Book per Share is €0.02. Theralase Technologies' overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Theralase Technologies (FRA:TTX), the current Cyclically Adjusted Book per Share is €0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Theralase Technologies (FRA:TTX) Overvalued in 2026?

Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued. The current stock price of €0.16 is trading 57% above its estimated GF Value™ of €0.10. GuruFocus considers Theralase Technologies to be Significantly Overvalued.

Key valuation signals for FRA:TTX:

  • Cyclically Adjusted Book per Share: €0.02
  • GF Value™: €0.10 vs. price of €0.16 (57% above fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the FRA:TTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Theralase Technologies Business Description

Other Exchanges TLTFF:USATLT:Canada
Address 41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
47GF Score

Get the complete analysis for FRA:TTX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.16
Price
€0.10
GF Value